VKTX: No Cardio Toxicity Concerns for VK2809

By David Bautz, PhD



Business Update

No Cardiovascular Toxicity Concerns for VK2809

Following release of the Phase 2 data for VK2809 in patients with hypercholesterolemia and nonalcoholic fatty liver disease (NAFLD), which we believe show the potential for VK2809 to be a best-in-class treatment in NAFLD and nonalcoholic steatohepatitis (NASH), we began to hear from investors who were questioning the potential for VK2809-induced cardiotoxicity. While we are unsure of where these concerns originated from, we analyzed the available data and have concluded that any concerns surrounding cardiotoxicity from VK2809 are unwarranted. For interested investors, we provide a link to what we believe are the most pertinent manuscripts (Erion et al., 2007; Fujitaki et al., 2008).

Before getting into the data it is necessary to give a brief overview of VK2809 and its activation. VK2809 is an agonist of the thyroid hormone receptor beta (TRβ). There are two major isoforms of the thyroid hormone receptor (TR), TRα and TRβ, which have markedly different expression patterns. TRα expression is highest in the heart and brain while TRβ expression is highest in the liver (Bookout et al., 2006). Multiple studies have shown a clear role for TRα in regulating heart rate (Wikström et al., 1998) and TRβ regulating serum cholesterol levels (Weiss et al., 2002; O’Shea et al., 2002). Thus, compounds that can selectively alter TRβ function with little to no effect on TRα could have a beneficial effect on lipid metabolism while avoiding potentially deleterious cardiac side effects.

As shown in the following figure, VK2809 (referred to in the figure as MB07811) is a prodrug that is converted to its active form by the enzyme cytochrome P450 3A4 (CYP3A4). CYP3A4 is expressed predominantly in the liver, but also in the small intestine.

View Exhibit I

Upon oral administration, VK2809 exhibits significant first-pass hepatic extraction (~55%) and is not subject to enterohepatic recirculation. What this means is that a significant portion of the drug is quickly metabolized in the liver to the active form and is unable to reach systemic circulation. The highly negatively charged phosphonic acid group on activated VK2809 (MB07344) essentially ‘traps’ the molecule inside the cell (highly charged compounds typically cannot passively diffuse across the cellular membrane) and also results in a decreased affinity for cellular transporters that transport carboxylates, again decreasing the chance for the active compound to reach the circulation in appreciable amounts.

We believe that detractors of VK2809 have taken the available pharmacokinetic data and misinterpreted it in an effort to exaggerate the potential for VK2809 to both get into the heart and to activate TRα, which in theory could lead to unwanted side effects. The following table shows the level of radioactive VK2809 found in various tissues following an oral dose in rats. We believe it is important to highlight a couple of things from the table: 1) the prodrug was radiolabeled, thus it is not possible to differentiate whether the radioactive compound measured is the prodrug or the activated compound; 2) there is a large amount of drug in the stomach, small intestine, and large intestine, which is not surprising given the drug was orally administered; 3) the amount of drug found in the heart (0.36 ± 0.36 nmol/g) is very small and close to the limit of quantitation; and 4) after 24 hours there is essentially no drug remaining in the heart and the highest concentration of drug is seen in the liver. The takeaways from this table are that it is conceivable that some activated VK2809 is entering the circulation (due to its high concentration in the intestine and the presence of intestinal CYP3A4), however it is clearly not being concentrated in the heart and any VK2809 that in fact penetrates cardiac tissue is not accumulating.

We find it most probable that any VK2809 found in the heart is the prodrug (as it can more easily passively diffuse across the cell membrane), and not the activated form. If this is the case, it is not a concern as there is no expression of CYP3A4 in cardiac tissue to convert the prodrug to its active form. In addition, there is no meaningful expression of TRβ in the heart and the prodrug itself has very low affinity for TRα (prodrug VK2809 Ki = 12.5 ± 0.6 μM; activated VK2809 TRβ Ki = 2.17 ± 0.41 nM). In other words, the radioactivity observed in heart is most likely due to the presence of the prodrug, which doesn’t bind to TR. While our comments are speculative, we believe they’re more consistent with the chemical and biological characteristics of VK2809 than the alternative proposal, which is based on the idea that activated VK2809 is present (it’s far less likely to penetrate cell membranes compared with the prodrug) and that it’s accumulating (it isn’t).

View Exhibit II

This data is further supported by radiolabel data from experiments in monkeys. Just as in rats, following oral administration the majority of VK2809 is found in liver and any drug found in cardiac tissue is no longer present after 12 hours. This again shows that there is no cardiac accumulation of VK2809.

View Exhibit III

Additional data supporting the cardiac safety of VK2809 comes from gene expression data showing that in contrast to T3 (white bars) or KB-141 (non-liver targeted TR agonist, striped bars), VK2809 (gray bars) did not cause an increase in expression of genes known to be sensitive to TR activation. In fact, cardiac gene expression changes due to VK2809 are similar to vehicle (black bars). Thus, even if VK2809 was getting into cardiac tissue it does not appear to have any effect on TR activation.

View Exhibit IV

Lastly, no TRα specific changes or cardiac toxicity have been seen to date in animals or humans. In rats, dosing with VK2809 caused no significant change in heart rate, body weight, left ventricular pressure, or heart weight. Perhaps most importantly, in the Phase 2 study of VK2809 there was no sign of a change in body weight, heart rate, or blood pressure, which would be indicative of potential TRα activation. Thus, we don’t find any basis to support the argument that VK2809 has the potential to cause cardiotoxicity.


We are glad to have been able to take a close look at the available data regarding VK2809 cardiac safety and are confident in our conclusion that, based on the available data, there is no safety concern. We are unsure of the origin of this argument against VK2809 (although we heard it from multiple sources), but it is not supported by the published data that are often cited as evidence. We surmise that it is an attempt to detract from the very encouraging data for the drug showing a robust ability to decrease liver fat in patients with NAFLD, which we believe is an excellent read-through for a NASH population. We believe VK2809 could become a best-in-class drug, and we are looking forward to additional updates from Viking (NASDAQ:VKTX) regarding the Phase 2b clinical trial in NASH patients, which we continue to anticipate initiating in the second half of 2019. In addition to that update, we anticipate the company presenting additional data from the 5 mg dosing cohort from the Phase 2 trial of VK2809 at EASL 2019 in April. Our thesis for Viking remains unchanged, and it continues to be one of our top picks among small-cap biotech stocks. Our valuation remains at $28.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR. 

DISCLOSURE: Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $30,000 annually for these services. Full Disclaimer HERE.